---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-027398"
form_type: "8-K"
ticker: "FHTX"
cik: "0001822462"
company_name: "Foghorn Therapeutics Inc."
filed_at: "2023-08-04T23:59:59+00:00"
generated_at: "2026-06-12T06:18:45.816051+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Foghorn Therapeutics Q2 net loss $29.5M; cash $284.3M; AML combo study starting Q3 2023

## Summary
- Net loss of $29.5M for Q2 2023 vs $27.3M in Q2 2022.
- Cash, cash equivalents & marketable securities of $284.3M, providing runway into H2 2025.
- Collaboration revenue $5.6M (up from $4.5M YoY), primarily from Lilly agreement.
- FHD-286 combination study in AML to begin Q3 2023 after resolving clinical hold.
- Pipeline advancing: selective BRM, ARID1B, EP300, CBP programs toward IND; six new INDs targeted in 4 years.

## SEC filing metadata
- accession: 0001628280-23-027398
- form_type: 8-K
- ticker: FHTX
- cik: 0001822462
- company_name: Foghorn Therapeutics Inc.
- filed_at: 2023-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822462/000162828023027398/0001628280-23-027398-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822462/000162828023027398/fhtx-20230804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-027398
- JSON: https://secwatch.observer/filing/0001628280-23-027398.json
- Plain text: https://secwatch.observer/filing/0001628280-23-027398.txt

## Key facts
- Earnings Releases
  Foghorn Therapeutics Inc. reported the quarter ended June 30, 2023 results: revenue $5.6 million, net income $29.5 million.
  - Period: the quarter ended June 30, 2023
  - Revenue: $5.6 million
  - Net income: $29.5 million
  - Result: reported results
  source text: Collaboration revenue was $5.6 million for the three months ended June 30, 2023, compared to $4.5 million for the three months ended June 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1822462/000162828023027398/0001628280-23-027398-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.